湖北亨迪药业股份有限公司独立董事 关于公司第二届董事会第二次会议相关事项的独立意见 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第二次会议 于 2023 年 8 月 24 日以现场和通讯方式召开。根据《上市公司独立董事规则》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等相关法律、法规及规范性文件的规 定以及《公司章程》、《独立董事工作制度》等的规定，我们作为公司的独立董 事，在认真阅读了第二届董事会第二次会议相关会议资料、听取了有关人员汇报 的基础上，本着实事求是的原则，对相关事项发表独立董事意见如下： 一、关于 2023 年半年度对外担保情况的独立意见 公司能够严格遵循《公司法》等法律法规及《公司章程》的相关规定，严格 履行对外担保的审议程序，严格控制对外担保风险。2023 年上半年度，公司没有 为控股股东提供担保，也没有为其他关联方、任何非法人单位或个人提供担保， 不存在与《关于规范上市公司与关联方资金往来及上市公司对外担保若干问题的 通知》（证监发[2003]56 号）、《关于规范上市公司对外担保行为的通知》（证 监发 ...

Group 1: Company Overview - As of May 19, 2023, the number of shareholders is 31,819 [2] - The company focuses on the production of ibuprofen and its derivatives, aiming to establish a global production base for antipyretic and analgesic drugs [3] Group 2: Future Projects and Developments - The company plans to advance the construction of projects with an annual capacity of 5,000 tons of ibuprofen and 200 tons of ibuprofen lysinate [3] - It aims to enhance its product system in cardiovascular, anti-tumor, and anticholinergic drugs, with projects like 10 tons/year of abiraterone acetate and 2 tons/year of imatinib mesylate [3] - The company is also working on the development of various formulations, including sustained-release ibuprofen capsules and injection products [3] Group 3: Sales and Marketing Strategy - The sales model for raw materials is primarily direct sales, supplemented by distribution, while formulations are sold domestically through a distribution model [4] - The company emphasizes a customer-centric sales philosophy [4] Group 4: Research and Development Focus - The company prioritizes new drug research, particularly in ibuprofen derivatives and specialty raw materials for cardiovascular and anti-tumor applications [3] - Currently, there are no traditional Chinese medicine products or research initiatives [4] Group 5: Vision and Goals - The company aims to become a significant domestic base for non-steroidal anti-inflammatory raw materials and specialty raw materials, promoting synergistic development between raw materials and formulations [4]

证券代码：301211 证券简称：亨迪药业 湖北亨迪药业股份有限公司投资者关系活动记录表 编号：2023-001 投资者关 系活动类 别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 新闻发布会 □路演活动 现场参观 参与单位 名称及人 员姓名 社会公众、投资者等 时间 2023 年 5 月 18 日 15:30——17:00 地点 公司通过互动易"云访谈"（ http://irm.cninfo.com.cn）采用网 络远程的方式召开业绩说明会 上市公司 接待人员 姓名 董事长程志刚先生 总经理梁群先生 独立董事傅仁辉先生 副总经理、董事会秘书高健先生 财务总监易廷浩先生 投资者关 系活动主 要内容介 绍 公司于 2023 年 4 月 25 日披露了《2022 年年度报告》。为了让 广大投资者进一步了解公司 2022 年度经营情况，公司于 2023 年 5 月 18 日 15:30－17:00 通过互动易"云访谈"举办了 2022 年年度 业绩说明会。 互动交流内容如下： 1、去年亨迪业绩上涨多少 | 答 ： 谢 谢 您 对 公 司 的 关 注 。 2022 年 ， 公 司 营 业 收 入 | | - ...

证券代码：301211 证券简称：亨迪药业 公告编号：2023-019 湖北亨迪药业股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）《2022 年年度报告》经 公司第一届董事会第十七次会议和第一届监事会第十次会议审议通过，并于 2023 年 4 月 24 日披露于巨潮资讯网（http://www.cninfo.com.cn）。 为便于广大投资者进一步了解公司 2022 年经营情况，公司定于 2023 年 5 月 18 日召开 2022 年度网上业绩说明会，现将有关信息公告如下： 一、业绩说明会基本情况 1、业绩说明会召开时间 2023 年 5 月 18 日（星期四）下午 15：30-17:00 2、业务说明会召开方式 三、会议问题征集 为充分尊重投资者、提升本次业绩说明会的交流效果和针对性，现就公司 2022 年度业绩说明会提前向投资者公开征集问题，投资者可于 2023 年 5 月 18 日 15:30 前访问 http://irm.cninfo.com.cn ...

Revenue and Profit Growth - Revenue for the first quarter of 2023 increased by 50.72% to RMB 193,286,953.47 compared to the same period last year[11] - Operating revenue for the first quarter of 2023 was RMB 193,286,953.47, a 50.7% increase compared to RMB 128,246,403.15 in the same period last year[33] - Net profit attributable to shareholders rose by 42.76% to RMB 39,922,932.84 year-over-year[11] - Net profit for the first quarter of 2023 was RMB 39,922,932.84, a 42.7% increase compared to RMB 27,964,503.94 in the same period last year[34] - The company's basic and diluted earnings per share both grew by 41.67% to RMB 0.17[11] - Basic earnings per share for the first quarter of 2023 were RMB 0.17, compared to RMB 0.12 in the same period last year[34] Cash Flow and Financial Position - Operating cash flow turned negative at RMB -15,751,558.42, a decrease of 126.77% from the previous year[11] - Net cash flow from operating activities turned negative at -15,751,558.42, compared to a positive 58,835,705.46 in the previous period[36] - Investment cash flow decreased significantly by 1,845.93% to RMB -15,747,092.81 due to payments for fundraising projects[16] - Net cash flow from investing activities was -15,747,092.81, a significant decrease from -809,231.50 in the previous period[36] - Cash and cash equivalents at the end of the first quarter of 2023 were RMB 1,825,739,376.30, a decrease of RMB 32,349,494.75 compared to the beginning of the period[31] - Monetary funds decreased to 1,825,739,376.30 yuan from 1,858,088,871.05 yuan at the beginning of the year[22] - Total liabilities and owner's equity at the end of the first quarter of 2023 were RMB 2,480,787,021.44, a slight decrease compared to RMB 2,497,721,443.51 at the end of the previous period[33] - Total assets slightly declined by 0.68% to RMB 2,480,787,021.44 compared to the end of the previous year[11] - Total assets decreased to 2,480,787,021.44 yuan from 2,497,721,443.51 yuan at the beginning of the year[22][23] R&D and Strategic Investments - R&D expenses increased by 53.89% to RMB 7,117,899.04 due to the company's "API + Formulation" integration strategy[16] - R&D expenses for the first quarter of 2023 were RMB 7,117,899.04, a 53.9% increase compared to RMB 4,625,339.65 in the same period last year[33] - Cash paid for the purchase of fixed assets, intangible assets, and other long-term assets increased sharply to 15,753,734.40 from 767,134.50[36] Assets and Liabilities - Current assets decreased to 2,198,104,491.56 yuan from 2,226,895,374.35 yuan at the beginning of the year[22] - Non-current assets increased to 282,682,529.88 yuan from 270,826,069.16 yuan at the beginning of the year[22][23] - Current liabilities decreased to 151,736,493.24 yuan from 208,909,427.09 yuan at the beginning of the year[23] - Non-current liabilities remained stable at 12,303,450.57 yuan compared to 12,312,563.79 yuan at the beginning of the year[23] - Shareholders' equity increased by 1.77% to RMB 2,316,747,077.63[11] - Shareholders' equity increased to 2,316,747,077.63 yuan from 2,276,499,452.63 yuan at the beginning of the year[23] - The company's total owner's equity at the end of the first quarter of 2023 was RMB 2,316,747,077.63, an increase of RMB 40,247,625.00 compared to the end of the previous period[33] Operating Activities and Expenses - Prepayments surged by 87.00% to RMB 34,389,436.84, driven by increased advance payments to suppliers[16] - Contract liabilities decreased by 59.88% to RMB 27,969,583.04 due to reduced prepayments from customers[16] - Sales of goods and services received cash of 140,480,784.29, an increase from the previous period's 129,945,261.07[36] - Cash received from other operating activities decreased to 13,439,650.24 from 19,657,544.73 in the previous period[36] - Total cash inflows from operating activities were 153,929,298.28, down from 158,915,828.76 in the previous period[36] - Cash paid for goods and services increased significantly to 100,153,085.60 from 57,535,278.18[36] - Cash paid to employees and for employee benefits rose to 27,871,641.79 from 22,166,248.58[36] - Total cash outflows from operating activities surged to 169,680,856.70 from 100,080,123.30[36] Financial Expenses and Other Items - The company's financial expenses for the first quarter of 2023 were RMB -11,607,887.42, mainly due to interest income of RMB 12,295,014.61[33] - Accounts receivable decreased to 70,891,650.90 yuan from 71,675,405.36 yuan at the beginning of the year[22] - Inventory increased to 122,046,297.99 yuan from 114,701,717.43 yuan at the beginning of the year[22] - Fixed assets decreased to 121,244,762.73 yuan from 126,308,041.13 yuan at the beginning of the year[22] - The company's first-quarter report for 2023 was unaudited[38]

Fundraising and Financial Management - The total amount of funds raised by the company is 154,800,000 CNY, with a net amount of 140,073,230 CNY after deducting issuance costs[3]. - As of December 31, 2022, the company has cumulatively invested 9,458,820 CNY in four fundraising projects, with a remaining balance of 135,372,100 CNY in the fundraising account[3]. - The cumulative interest income from the fundraising account, after deducting handling fees, is 4,757,680 CNY[3]. - The company has not yet utilized 135,372,100 CNY of the raised funds, which are currently held in a dedicated fundraising account[15]. - The company plans to distribute a cash dividend of 4 CNY per 10 shares (including tax) based on a total of 240,000,000 shares[20]. - The company has made adjustments to the use of raised funds amounting to 30,542,550 CNY, which accounts for 21.80% of the total raised funds[15]. - The company has allocated 6,000 million RMB of raised funds for permanent working capital, completed on November 30, 2022[56]. - The company plans to use an additional 15,042.55 million RMB of raised funds for the high-end pharmaceutical formulation internationalization project[56]. - The total investment in committed projects amounts to 140,073.23 million RMB, with a total expected return of 9,458.82 million RMB[53]. Financial Performance - The company's operating revenue for 2022 was ¥514,911,768.91, a decrease of 4.76% compared to ¥540,622,560.29 in 2021[29]. - Net profit attributable to shareholders for 2022 was ¥125,723,912.42, an increase of 3.35% from ¥121,649,369.36 in 2021[29]. - The net profit after deducting non-recurring gains and losses was ¥119,704,115.02, reflecting a significant increase of 16.48% from ¥102,769,705.21 in 2021[29]. - The net cash flow from operating activities surged by 102.28% to ¥250,794,526.06, compared to ¥123,984,034.41 in the previous year[29]. - Basic and diluted earnings per share decreased by 23.53% to ¥0.52, down from ¥0.68 in 2021[29]. - Total assets at the end of 2022 reached ¥2,497,721,443.51, marking a 7.18% increase from ¥2,330,303,998.61 at the end of 2021[29]. - Net assets attributable to shareholders increased by 2.42% to ¥2,276,499,452.63, compared to ¥2,222,775,540.21 at the end of 2021[29]. - The company reported a weighted average return on equity of 5.57%, down from 15.98% in 2021, indicating a decline of 10.41%[29]. - The total revenue for 2022 was ¥514,911,768.91, a decrease of 4.76% compared to ¥540,622,560.29 in 2021[85]. - The revenue from active pharmaceutical ingredients (APIs) was ¥426,888,294.01, accounting for 82.91% of total revenue, down 8.12% from ¥464,614,761.04 in 2021[85]. - The revenue from formulations increased by 15.08% to ¥86,466,441.20, up from ¥75,134,832.89 in 2021, representing 16.79% of total revenue[85]. - The company achieved a gross margin of 22.86% for APIs, down 5.62% from the previous year, while the gross margin for formulations was 61.18%, an increase of 11.30%[85]. - The sales volume of APIs decreased by 26.31% to 2,871.28 tons in 2022, while production volume decreased by 11.62% to 3,203.68 tons[88]. - The inventory of ibuprofen APIs increased by 66.51% to 310.05 tons, indicating a strategic stockpiling[88]. - The company signed significant sales contracts totaling ¥103,969,879.52, which accounted for 20.19% of total annual sales[91]. - The company has established itself as a qualified global supplier for major pharmaceutical companies, enhancing its market reputation[82]. - The domestic revenue increased by 4.09% to ¥277,030,607.46, while overseas revenue decreased by 13.34% to ¥237,881,161.45[85]. Research and Development - Research and development expenses amounted to ¥19,844,831.98, representing 3.85% of operating revenue, an increase from 3.38% in 2021[95]. - The number of R&D personnel increased by 5.71% to 111 in 2022, compared to 105 in 2021[118]. - The company plans to enhance its R&D capabilities and CDMO services by accelerating the construction of the Wuhan Hendi R&D project[127]. - The company has completed several new product developments, including various formulations of ibuprofen and other APIs, to enrich its product portfolio[1]. - The company has filed patents for innovative production methods, including a method for industrial preparation of calcium docetaxel and ibuprofen L-lysine salt, showcasing its commitment to R&D[76]. - The company has achieved a significant milestone by completing the BE filing for various formulations, including tolvaptan tablets, indicating readiness for market entry[76]. - The company emphasizes cost reduction and efficiency improvement through process optimization and digital transformation, enhancing its product competitiveness[76]. - The company is actively expanding its product line in non-steroidal anti-inflammatory drugs and oncology drugs, which is expected to increase its operational profitability[79]. Market and Industry Trends - The pharmaceutical industry in China is undergoing significant reforms, with over 320 policies issued in 2022 to encourage innovation and strengthen regulation[51]. - The company is focusing on enhancing drug supply security and quality, aligning with national policies for high-quality development in the pharmaceutical sector[51]. - The company is committed to developing drugs for rare diseases and children's medications, with incentives for first approvals and market exclusivity[51]. - The company aims to establish a global manufacturing base for antipyretic and analgesic drugs, focusing on the production of 5,000 tons/year of ibuprofen and 200 tons/year of ibuprofen lysine salt, enhancing its global competitiveness[68]. - The company is developing a "special raw material drug manufacturing base" with projects including 10 tons/year of abiraterone acetate and 500 tons/year of sodium docetaxel, aiming to become a leading manufacturer in this sector[68]. - The company is advancing the construction of a regional production base for solid formulations in Hubei Province, focusing on the consistency evaluation of various formulations including ibuprofen sustained-release capsules and injections[71]. - The fluctuation of the RMB exchange rate impacts the company's performance, with appreciation leading to decreased competitiveness in overseas sales and potential foreign exchange losses during the receivable period[149]. Corporate Governance and Compliance - The company has committed to transparency and accuracy in its financial reporting, ensuring no misleading statements or omissions[19]. - The company operates independently from its controlling shareholders, ensuring a complete and independent business system[160]. - The company has complied with various regulatory requirements and governance standards to protect the rights of investors and stakeholders[154]. - The company is adapting to the evolving regulatory landscape in the pharmaceutical industry, which includes new policies that may affect market dynamics and operational strategies[171]. - The company held 2 shareholder meetings during the reporting period, ensuring compliance with legal regulations and providing equal rights to all shareholders[175]. - The board of directors consists of 8 members, including 3 independent directors, fulfilling the requirements of laws and regulations[176]. - The supervisory board is composed of 3 members, effectively overseeing the company's operations and protecting shareholder interests[179]. - The company has established a transparent governance structure, including specialized committees to support decision-making processes[176]. - The company has not reported any incidents of fund occupation by the controlling shareholder during the reporting period[183]. - The company continues to focus on maintaining operational independence and protecting the rights of minority shareholders[183].

湖北亨迪药业股份有限公司 2022 年第三季度报告 证券代码:301211 证券简称：亨迪药业 公告编号: 2022-032 湖北亨迪药业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1. 董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2. 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明: 保证季度报告中财务信息的真实、准确、 完整。 3. 第三季度报告是否经过审计 □是 ☑否 l 湖北亨迪药业股份有限公司 2022年第三季度报告 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |----------------------------------------------------|----------------------|-------------------------|-- ...

湖北亨迪药业股份有限公司 2022 年半年度报告全文 湖北亨迪药业股份有限公司 2022 年半年度报告 2022-028 biocause 2022 年 8 月 l 湖北亨迪药业股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人程志刚、主管会计工作负责人易廷浩及会计机构负责人(会计 主管人员)全纯华声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告"第三节 管理层讨论与分析"中"十、公司面临的风险和 应对措施"部分,详细描述了公司经营中可能存在的风险及应对措施,敬请 投资者关注相关内容。 公司计划不派发现金红利，不送红股,不以公积金转增股本。 2 湖北亭迪药业股份有限公司 2022 年半年度报告全文 目录 | --- | --- | |--------------------------------|-------| | | | | 第一节 重要提示、目录和释义 | ...

湖北亨迪药业股份有限公司 2022 年第一季度报告全文 证券代码：301211 证券简称：亨迪药业 公告编号：2022-019 湖北亨迪药业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | 本报告期 ...

湖北亨迪药业股份有限公司 2021 年年度报告全文 湖北亨迪药业股份有限公司 2021 年年度报告 2022-011 2022 年 04 月 1 湖北亨迪药业股份有限公司 2021 年年度报告全文 公积金向全体股东每 10 股转增 0 股。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人程志刚、主管会计工作负责人易廷浩及会计机构负责人(会计主 管人员)全纯华声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 | --- | |-----------------------------------------------------------------------------------------| | | | 公司在本报告"第三节 管理层讨论与分析"中"十一、公司未来发展的展 | | 望"部分，详细描述 ...